PCN90 - COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF NILOTINIB FOR THE SECOND LINE TRATMENT OF CHRONIC MIELOID LEUKEMIA IN THE RUSSIAN FEDERATION
Oct 1, 2018, 00:00 AM
10.1016/j.jval.2018.09.172
https://www.valueinhealthjournal.com/article/S1098-3015(18)33472-7/fulltext
Section Title :
Section Order :
1090
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(18)33472-7&doi=10.1016/j.jval.2018.09.172